Drug intelligence / Profile preview

naltrexone + gabapentin

Development stage: Unknown
Lead developer: Endo International
Modality: Small Molecules
Administration: Oral

Overview

A combination of naltrexone and gabapentin used primarily for the treatment of alcohol use disorder. Naltrexone works by blocking opioid receptors in the brain, reducing the rewarding effects of alcohol and decreasing cravings. Gabapentin helps with symptoms that often lead to relapse during early abstinence, such as insomnia, mood instability, and withdrawal symptoms. Clinical trials have shown that this combination can improve drinking outcomes compared to naltrexone alone, particularly during the first 6 weeks of treatment.

Targets

CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (α2δ-2)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on naltrexone + gabapentin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on naltrexone + gabapentin.

Explore the full profile